An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms RESIDD
- Sponsors Ranbaxy Laboratories
- 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials RegistryACTRN12607000473460).
- 27 Nov 2007 New trial record.